Beto Financial Group’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Beto Financial Group’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232K	Buy	+6,833	New	+$233K	0.14%	134

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $208M AUM 30.96% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Beto Financial Group's FTXH Position: Q1 2026 in Review

Beto Financial Group opened a new position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2026: 6,833 shares worth $232K. The stake represents 0.14% of the portfolio and ranks #134 among its holdings.

32 funds tracked by Wall St. Rank hold FTXH as of Q1 2026.

Beto Financial Group held 6,833 shares of First Trust Nasdaq Pharmaceuticals ETF worth $232K as of Q1 2026.
First Trust Nasdaq Pharmaceuticals ETF was a new Beto Financial Group position in Q1 2026.
First Trust Nasdaq Pharmaceuticals ETF made up 0.14% of Beto Financial Group's portfolio in Q1 2026, its #134 holding.
32 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2026.

Based on Beto Financial Group's 13F filing for Q1 2026, filed 11 May 2026.